Abstract Submission

Thank you to all abstract submitters for their contribution.

The regular abstract submission is closed and the notifications have been sent out, by email, end of March 2019.

The late breaking science abstract submission is closed and the notifications will be sent out by end of April.

ABSTRACT PUBLICATION

The accepted regular abstracts will be published on this website and also in Maturitas journal (June 2019 issue), the official EMAS journal.

Maturitas is an international multidisciplinary peer reviewed scientific journal of midlife health and beyond. https://www.maturitas.org/

Should you have any questions related to Abstracts, please contact us by email to: emas2019-abstract@kit-group.org

Maximum Number of Words
2,500 characters (including spaces)

Tables/Pictures
No tables are allowed.
No pictures are allowed.

Authors
Authors and institution must be named, the presenter (or presenting author) must be underlined.

Presenting authors should register upon submitting their abstract. Registration must be completed at the latest upon confirmation that the abstract has been accepted as an oral or poster presentation.

Contact

Please contact the EMAS 2019 Secretariat at: emas2019-abstract@kit-group.org for all abstracts enquiries.

Notification of acceptance
All abstracts will be peer reviewed and authors notified in March 2019 whether or not their abstract has been accepted as an oral or a poster presentation.

The Scientific Committee invites worldwide experts to submit their abstracts for review and possible presentation on the following topics:

1. Menopause and climacteric

1.1. Climacteric symptoms

1.2. Complementary and alternative medicine

1.3. Diet, lifestyle and dietary supplements

1.4. Female sexual dysfunction

1.5. Menopausal hormone therapy, sex steroids and receptor modulators

1.6. Non-hormone therapy

1.7. Osteoporosis

1.8. Ovarian ageing

1.9. Perimenopause

1.10. Premature menopause

1.11. Quality of life

1.12. Urogenital ageing

 

2. Gynaecology and women’s health

2.1. Assisted reproduction

2.2. Benign breast disease

2.3. Benign gynaecology

2.4. Breast cancer

2.5. Contraception and fertility

2.6. Endocrine disrupters

2.7. Endocrinology

2.8. Gynaecological cancer

2.9. Non-hormone therapy

2.10. Sex steroids and receptor modulators

2.11. Sexual health

2.12. Urogynaecology

 

3. Andropause and men’s health

3.1. Endocrinology

3.2. Male sexual dysfunction

3.3. Cancer

3.4. Urinary incontinence

3.5. Complementary and alternative therapies

3.6. Androgens and androgen receptor modulators

4. Midlife health and ageing

4.1. Cardiovascular disease

4.2. Complementary and alternative therapies

4.3. Cross-cultural differences

4.4. Degenerative disorders

4.5. Dementia and cognition

4.6. Depression and anxiety

4.7. Diet and lifestyle

4.8. Dietary supplements

4.9. Endocrinology of aging

4.10. Epidemiology

4.11. Frailty

4.12. Gender differences in chronic disease

4.13. Health and social care

4.14. Metabolic disorders

4.15. Migraine

4.16. Obesity

4.17. Occupational medicine

4.18. Osteoporosis and arthritis

4.19. Predictors of disease in later life

4.20. Sarcopenia

4.21. Screening

4.22. Skin ageing

4.23. Sleep

 

5. Innovation

5.1. Basic science

5.2. Diagnostics

5.3. Drug discovery

5.4. E-health

5.4. Integrating research from bench to bed side

5.5. Nanomedicine

5.6. Regenerative medicine

5.7. Stem cells

5.8. Surgery

5.9. Workplace, menopause and ageing